Nelson Nadine, Xiang Shengyan, Zhang Xiaohong, Gilvary Danielle, Djeu Julie, Husain Kazim, Malafa Mokenge, Vohra Nasreen, Pilon-Thomas Shari, Ghansah Tomar
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States of America.
Department of Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States of America.
PLoS One. 2015 Jan 28;10(1):e0115546. doi: 10.1371/journal.pone.0115546. eCollection 2015.
Maintenance of T cell immune homeostasis is critical for adequate anti-tumor immunity. The transcription factor Ikaros is essential for lymphocyte development including T cells. Alterations in Ikaros expression occur in blood malignancies in humans and mice. In this study, we investigated the role of Ikaros in regulating T cell immune balance in pancreatic cancer mouse models.
Using our Panc02 tumor-bearing (TB) mouse model, western blot analysis revealed a reduction in Ikaros proteins while qRT-PCR showed no differences in Ikaros mRNA levels in TB splenocytes compared to control. Treatment of naïve splenocytes with the proteasomal inhibitor, MG132, stabilized Ikaros expression and prevented Ikaros downregulation by Panc02 cells, in vitro. Western blot analyses showed a reduction in protein phosphatase 1 (PP1) and protein kinase CK2 expression in TB splenocytes while CK2 activity was increased. Immunofluorescence microscopy revealed altered punctate staining of Ikaros in TB splenocytes. Flow cytometry revealed a significant decrease in effector CD4+ and CD8+ T cell percentages but increased CD4+CD25+ regulatory T cells in TB splenocytes. Similar alterations in T cell percentages, as well as reduced Ikaros and CK2 but not PP1 expression, were observed in a transgenic, triple mutant (TrM) pancreatic cancer model. Ikaros expression was also reduced in enriched TB CD3+ T cells. MG132 treatment of naïve CD3+ T cells stabilized Ikaros expression in the presence of Panc02 cells. Western blots showed reduced PP1 and CK2 expression in TB CD3+ T cells.
CONCLUSIONS/SIGNIFICANCE: The results of this study suggest that the pancreatic tumor microenvironment may cause proteasomal degradation of Ikaros, possibly via dysregulation of PP1 and CK2 expression and activity, respectively. This loss of Ikaros expression may contribute to an imbalance in T cell percentages. Ikaros may potentially be a therapeutic target to restore T cell homeostasis in pancreatic cancer hosts, which may be critical for effective anti-tumor immunity.
维持T细胞免疫稳态对于充分的抗肿瘤免疫至关重要。转录因子Ikaros对于包括T细胞在内的淋巴细胞发育必不可少。在人类和小鼠的血液恶性肿瘤中,Ikaros表达会发生改变。在本研究中,我们在胰腺癌小鼠模型中研究了Ikaros在调节T细胞免疫平衡中的作用。
使用我们的荷瘤(TB)Panc02小鼠模型,蛋白质印迹分析显示Ikaros蛋白减少,而qRT-PCR显示与对照相比,TB脾细胞中Ikaros mRNA水平没有差异。用蛋白酶体抑制剂MG132处理未活化的脾细胞可稳定Ikaros表达,并在体外防止Panc02细胞使Ikaros下调。蛋白质印迹分析显示TB脾细胞中蛋白磷酸酶1(PP1)和蛋白激酶CK2表达减少,而CK2活性增加。免疫荧光显微镜检查显示TB脾细胞中Ikaros的点状染色发生改变。流式细胞术显示TB脾细胞中效应性CD4 +和CD8 + T细胞百分比显著降低,但CD4 + CD25 +调节性T细胞增加。在转基因三突变(TrM)胰腺癌模型中观察到T细胞百分比有类似变化,以及Ikaros和CK2表达降低,但PP1表达未降低。富集的TB CD3 + T细胞中Ikaros表达也降低。用MG132处理未活化的CD3 + T细胞可在存在Panc02细胞的情况下稳定Ikaros表达。蛋白质印迹显示TB CD3 + T细胞中PP1和CK2表达降低。
结论/意义:本研究结果表明,胰腺肿瘤微环境可能分别通过PP1和CK2表达及活性的失调导致Ikaros的蛋白酶体降解。Ikaros表达的这种丧失可能导致T细胞百分比失衡。Ikaros可能潜在地成为恢复胰腺癌宿主中T细胞稳态的治疗靶点,这对于有效的抗肿瘤免疫可能至关重要。